The second recurrence of Mycobacterium avium complex lung disease after successful treatment for first recurrence

The recurrence rate of Mycobacterium avium complex (MAC) lung disease (LD) after successful treatment is approximately 10–48% [1–3]. These episodes represent true relapse from the same MAC strain or a reinfection with a new strain [1, 2, 4]. Nodular bronchiectatic (NB) type, old age, lower body mass index (BMI) and M. avium isolates are related to recurrence [3, 5, 6]. Approximately 60% of patients who are successfully treated for their first recurrence of MAC lung disease eventually experience a second recurrence. Approximately half of the second recurrence patients require anti-MAC treatment. http://ow.ly/3G2R30meImC

• Publication year

  2018

• Venue

  European Respiratory Journal

• Publication date

  2018-10-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1183/13993003.01038-2018PMID 30337449
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment Outcomes after Discontinuation of Ethambutol due to Adverse Events in Mycobacterium avium Complex Lung Disease

  2020cited by this paper
• Outcome of shorter treatment duration in non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease

  2020cited by this paper
• In Vitro MIC Values of Rifampin and Ethambutol and Treatment Outcome in Mycobacterium avium Complex Lung Disease

  2018cited by this paper
• Development of Macrolide Resistance and Reinfection in Refractory Mycobacterium avium Complex Lung Disease

  2018cited by this paper
• Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype

  2017cited by this paper
• Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course

  2017cited by this paper
• Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease

  2017cited by this paper
• British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)

  2017cited by this paper
• BTS guideline for oxygen use in adults in healthcare and emergency settings

  2017cited by this paper
• Infection Sources of a Common Non-tuberculous Mycobacterial Pathogen, Mycobacterium avium Complex

  2017cited by this paper
• Relapse versus Reinfection of Mycobacterium avium Complex Pulmonary Disease. Patient Characteristics and Macrolide Susceptibility.

  2016cited by this paper
• Host susceptibility to non-tuberculous mycobacterial infections.

  2015cited by this paper
• Risk Factors for Recurrence after Successful Treatment of Mycobacterium avium Complex Lung Disease

  2015cited by this paper
• Comparison of Clinical Features, Virulence, and Relapse among Mycobacterium avium Complex Species.

  2015cited by this paper
• Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease.

  2014cited by this paper
• Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis.

  2002cited by this paper

• Gallium Hematoporphyrin inhibits Mycobacteroides abscessus in vitro, including biofilm formation and stability.

  2025cites this paper
• Review of the Canadian Nontuberculous Mycobacterial Disease Landscape—Challenges and Opportunities

  2025cites this paper
• Bigger problems from smaller colonies: emergence of antibiotic-tolerant small colony variants of Mycobacterium avium complex in MAC-pulmonary disease patients

  2024cites this paper
• Treatment for non-tuberculous mycobacteria: challenges and prospects

  2024cites this paper
• Genome-scale analysis of Mycobacterium avium complex isolates from Portugal reveals extensive genetic diversity.

  2024cites this paper
• A novel repeat sequence-based PCR (rep-PCR) using specific repeat sequences of Mycobacterium intracellulare as a DNA fingerprinting

  2023cites this paper
• Nontuberculous Mycobacterial Pulmonary Disease: A Clinical and Radiologic Update.

  2021cites this paper
• Discontinuation rates attributed to adverse events and treatment outcomes between clarithromycin and azithromycin in Mycobacterium avium complex lung disease: A propensity score analysis.

  2020cites this paper
• Outcome of shorter treatment duration in non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease

  2020cites this paper
• Treatment Outcomes after Discontinuation of Ethambutol due to Adverse Events in Mycobacterium avium Complex Lung Disease

  2020cites this paper